Location: Home >> Virtual Special Issues >> Bioinformatics and Precision Medicine

Advances in Acute Myeloid Leukemia

Dear Colleagues,

The heterogeneity of acute myelogenous leukemia (AML) is recognized by the diverse molecular pathology of disease at diagnosis and at relapse. An estimated 21,450 patients will be diagnosed with AML in 2019 in the United States with only 28.3% surviving at 5 years with some molecular subtypes more amenable to therapy than others; emphasizing treatment of this disease represents an unmet clinical need. While anthracycline and cytarabine-based therapy is curative for a subset of patients, those of advanced age or with adverse-risk cytogenetic and molecular features experience poor outcomes. Recent advances have resulted in improved understanding of AML prosurvival pathways and mechanisms underpinning relapsed disease. These advances have broadened the AML therapeutic landscape to include eight new FDA-approved agents since 2017. Additionally, novel treatment strategies are being evaluated to improve outcomes of patients undergoing hematopoietic stem cell transplant (HSCT) outcomes, including targeting minimal residual disease (MRD) and employing post-transplantation maintenance strategies. This special issue aims to review dynamic changes in the field of AML including; advances in understanding the underlying disease pathophysiology, novel molecules to target prosurvival pathways, newly approved drugs for broad and single-gene targeted approaches, and strategies to optimize HSCT outcomes including MRD-directed treatment and post-transplant maintenance strategies.

Dr. Monica Mead

Dr. Gary Schiller

Guest Editors


Acute myeloid leukemia

Novel AML therapies

Minimal residual disease

Bone marrow transplant


Submission Deadline: 28 February 2020

Online Submission

Manuscripts should be submitted online through Hapres Online Submission System. Please visit Guide for Authors before submitting a manuscript. Authors are encouraged to submit a paper as soon as it is ready and don’t need to wait until the deadline. Submissions will be sent to peer-review in order of arrival. Accepted papers will be published continuously in Med One and then gathered together on the special issue webpage. We welcome Research articles, Review papers, Meta-Analysis articles, and Perspectives. There are no word limits for each article type. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for approval.


Virtual Special Issue (VSI) is a collection of papers centered around a specific topic, led by an expert (Guest Editor) in the field. Virtual Special Issues are an important component of our journal and cover current hot topics within the scope of the journal.

All papers belonging to a Virtual Special Issue will be gathered together on a single webpage. They are published in the regular issues of the journal as soon as publishable, and labeled as belonging to the Virtual Special Issue. A link from each paper will take you to the Virtual Special Issue website.

Submissions to Virtual Special Issues will undergo the same rigorous peer-review process as regular papers submitted to the journal.

Guest Editors

  • Dr. Monica Mead

    University of California, Los Angeles (UCLA Medical Center)

  • Dr. Gary Schiller

    University of California, Los Angeles (UCLA Medical Center)

Copyright © 2022 Hapres Co., Ltd. Privacy Policy | Terms and Conditions